URGN
UroGen Pharma Ltd.
$39.19
-0.32 (-0.81%)
At close · Jul 14
Market Cap
$1.91B
Shares
48,721,701
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$39.19
Open$39.53
Day$38.88–40.40
52W$13.79–40.40
Avg vol 30d700K
Short int6.2M · 12.8% float · 9.4d
Short vol81%
Last earningsMay 6, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 3, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.5 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+66%
above
Price vs 50-day avg
+25%
above
RSI (14)
70
neutral
MACD trend
Positive
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+32%
trailing
6-month return
+103%
trailing
YTD return
+67%
this year
Relative strength
+92%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $31 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
2 of 173 funds reported for Jun 30 · net +93.2K sh shares
Insider flow
Distributing
Net -$442.6K over 90 days · 100% sells
Short interest
Falling
12.76% of float · ▼ -5.2% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
173 holders — near 3-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
Revenue growth
+299%
Y/Y
Gross margin
8630%
contracting
Free cash flow
$-162.7M
Balance sheet
$14.3M
net debt
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Net product revenue for JELMYTO
· full-year 2026
Initiated
$97M – $101M
prior FY $109.79M
midpoint −9.8% Y/Y
Operating expenses
· full-year 2026
Initiated
$240M – $250M
Non-cash share-based compensation expense
· full-year 2026
Initiated
$20M – $24M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+66%
Bullish
Price vs 50-day avg
+25%
Bullish
RSI (14)
70
Neutral
MACD trend
Positive
Bullish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $31 › 200d $24 — 50d above 200d
Institutional flow
Accumulating
2 of 173 funds reported for Jun 30 · net +93.2K sh shares
Insider flow
Distributing
Net -$442.6K over 90 days · 100% sells
Short interest
Falling
12.76% of float · ▼ -5.2% MoM · 9.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
173 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $14
Now $39 · 95%
52-wk high $40
vs 200-day avg +66%
vs 50-day avg +25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| JELMYTO net product revenue | $21.7M | the quarter ended March 31, 2026 | — |
| repeat ZUSDURI prescribers | 103 | first quarter of 2026 | — |
| unique ZUSDURI prescribers | 256 | first quarter of 2026 | — |
| ZUSDURI net product revenue | $29.2M | first quarter of 2026 | — |
| covered lives with open access | 95% | Q1 2026 call | — |
| repeat prescribers | 103 | Q1 2026 call | — |
| unique prescribers | 256 | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
URGN
this stock
UroGen Pharma Ltd.
|
$1.91B | +67.3% | +0.0% | — | 12.8% |
|
ONC
BeOne Medicines Ltd.
|
$439.30B | +0.0% | +22179.2% | 894.0 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$120.89B | +5.1% | +46.2% | 28.3 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.79B | -14.9% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$53.77B | +2.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| URGN | +3.8% | +31.9% | +102.7% | +6.5% | +67.3% |
| SPY | +0.6% | +1.4% | +11.0% | +0.7% | +10.3% |
| vs SPY | +3.3% | +30.5% | +91.8% | +5.8% | +57.1% |